Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.
Recent viral outbreaks such as hMPV highlight the need for routine surveillance effective risk communication and boosting healthcare infrastructure Acute respiratory infections are a serious public he ...